WESTBOROUGH, Mass., Aug. 9, 2016 /PRNewswire-iReach/ -- Brie Stoianoff has joined The FDA Group in a newly created role asDirector of Quality & Service Assurance. Ms. Stoianoff comes to the company with more than 15 years of experience in the pharmaceutical and medical device industries. Over her career, she has been able to provide expert advice to tackle the quality
Photo - http://photos.prnewswire.com/prnh/20160808/396420
For the past two years, she successfully led Vision 28 LLC as the President & CEO. Prior to Vision 28, she held Director of Quality and Regulatory roles at Acumed and CompView Medical. She also spent time at Welch Allyn, AstraZeneca, Shire, and DuPont Pharmaceutical Company (now Bristol-Myers Squibb.)
More about The FDA Group
The FDA Group is a global leader in GxP auditing & remediation and regulatory services. Their purpose is to empower our clients to bring their life-changing healthcare products to the market and keep them there.
The FDA Group is able to do this by providing a world-class service experience. The way in which The FDA Group ensures a world-class service experience is by its proprietary talent selection process coupled with its deep-rooted corporate culture that includes 31 Fundamentals. These Fundamentals are the heart-beat of the organization and are focused on four areas: Core Values, Focus on Service, The Collaborative Way, and Personal Effectiveness.
For more information, contact:
Andrea Houlne(508) email@example.com
Media Contact: Andrea Houlne, The FDA Group, 508-926-8330, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE The FDA Group
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All